Floatz Rating
B62/100
Confidence
Indicative
Sponsor
Hoffmann-La Roche
Modality
Small molecule
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
52High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04222972CT.gov A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) | — | Terminated | — | — | — |
NCT03037385CT.gov Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Neoplasm Of Thorax
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Pralsetinib, Trans- (this asset) | Hoffmann-La Roche | P3 | B · 62 |
| Carboplatin | Fundación GECP | P3 | BB |
| Cis-Diamminedichloroplatinum Ii | Nanfang Hospital, Southern Medical University | P3 | B |
| Gefitinib | Chinese Society of Lung Cancer | P3 | B |
| Pembrolizumab | Amgen | P3 | B |
| Rivoceranib | Sichuan Cancer Hospital and Research Institute | P2 | B |
| L-Bupivacaine | Guy's and St Thomas' NHS Foundation Trust | P2/3 | B |
| Docetaxel | University of Turin, Italy | P3 | B |
| Vinorelbine Ditartrate | University of Turin, Italy | P3 | B |
+15 more in the Neoplasm Of Thorax cohort
Other indications for Pralsetinib, Trans-
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Neoplasm | — | P3 | BB · 67 |
| Germ Cell Tumor | — | P3 | BB · 66 |
| Respiratory System Disorder | — | P3 | BB · 66 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Pralsetinib, Trans- in Neoplasm Of Thorax. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pralsetinib-trans-neoplasm-of-thorax
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →